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Abstract
Background:  Carcinoma of the esophagus is an aggressive malignancy with an increasing
incidence. Its virulence, in terms of symptoms and mortality, justifies a continued search for optimal
therapy. The large and growing number of patients affected, the high mortality rates, the worldwide
geographic variation in practice, and the large body of good quality research warrants a systematic
review with meta-analysis.
Methods:  A systematic review and meta-analysis investigating the impact of neoadjuvant or
adjuvant therapy on resectable thoracic esophageal cancer to inform evidence-based practice was
produced.
MEDLINE, CANCERLIT, Cochrane Library, EMBASE, and abstracts from the American Society of
Clinical Oncology and the American Society for Therapeutic Radiology and Oncology were
searched for trial reports.
Included were randomized trials or meta-analyses of neoadjuvant or adjuvant treatments compared
with surgery alone or other treatments in patients with resectable thoracic esophageal cancer.
Outcomes of interest were survival, adverse effects, and quality of life. Either one- or three-year
mortality data were pooled and reported as relative risk ratios.
Results:  Thirty-four randomized controlled trials and six meta-analyses were obtained and
grouped into 13 basic treatment approaches.
Single randomized controlled trials detected no differences in mortality between treatments for
the following comparisons:
- Preoperative radiotherapy versus postoperative radiotherapy.
- Preoperative and postoperative radiotherapy versus postoperative radiotherapy. Preoperative
and postoperative radiotherapy was associated with a significantly higher mortality rate.
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- Postoperative chemotherapy versus postoperative radiotherapy.
- Postoperative radiotherapy versus postoperative radiotherapy plus protein-bound polysaccharide
versus chemoradiation versus chemoradiation plus protein-bound polysaccharide.
Pooling one-year mortality detected no statistically significant differences in mortality between
treatments for the following comparisons:
- Preoperative radiotherapy compared with surgery alone (five randomized trials).
- Postoperative radiotherapy compared with surgery alone (five randomized trials).
- Preoperative chemotherapy versus surgery alone (six randomized trials).
- Preoperative and postoperative chemotherapy versus surgery alone (two randomized trials).
- Preoperative chemoradiation therapy versus surgery alone (six randomized trials).
Single randomized controlled trials detected differences in mortality between treatments for the
following comparison:
- Preoperative hyperthermia and chemoradiotherapy versus preoperative chemoradiotherapy in
favour of hyperthermia.
Pooling three-year mortality detected no statistically significant difference in mortality between
treatments for the following comparison:
- Postoperative chemotherapy compared with surgery alone (two randomized trials).
Pooling three-year mortality detected statistically significant differences between treatments for
the following comparisons:
- Preoperative chemoradiation therapy versus surgery alone (six randomized trials) in favour of
preoperative chemoradiation with surgery.
- Preoperative chemotherapy compared with preoperative radiotherapy (one randomized trial) in
favour of preoperative radiotherapy.
Conclusion: For adult patients with resectable thoracic esophageal cancer for whom surgery is
considered appropriate, surgery alone (i.e., without neoadjuvant or adjuvant therapy) is
recommended as the standard practice.
Background
Carcinoma of the esophagus is an aggressive malignancy
that continues to kill more than 90% of people with the
disease within five years [1]. The incidence of adenocarci-
noma of the esophagus is rising faster than any other
malignancy [2]. In 2001, there were at least 1,450 deaths
due to esophageal cancer in Canada and many more peo-
ple suffered because of the disease [3]. Its virulence, in
terms of symptoms and mortality, justifies a continued
search for optimal therapy.
Surgical esophagectomy remains the preferred treatment
for clinically localized thoracic esophageal carcinoma
[1,4-6]. Two randomized trials comparing surgery alone
to radiation alone found surgery to be the better treatment
for resectable cancer [5,6]. Fok et al randomly assigned 39
patients to surgery and 35 patients to 45 to 53 Gy radia-
tion over four to five weeks [5]. The median survival time
and five-year survival rate for surgery were 21.6 months
and 16%, respectively, compared with 8.2 months and
7% for radiation (p < 0.05). Badwe et al compared 47 sur-
gical patients to 52 patients undergoing 50 Gy radiation in
28 fractions plus 15 Gy boost in 8 fractions or 15 Gy
brachytherapy [6]. Overall survival was better with surgery
(odds ratio [OR], 2.74; 95% confidence interval [CI], 1.51
to 4.98; log-rank p = 0.002). The swallowing status was
better in the surgery arm at six months after treatment (p
= 0.03). Survival data from these two trials were pooled.
The pooled results favoured surgery alone. There was no
statistical heterogeneity (X2 = 0.02, p = 0.9) and a 52% rel-
ative increase in the risk of death at three years with radi-
otherapy compared with surgery alone (relative risk ratio
[RR], 1.52; 95% CI, 1.23 to 1.86; p = 0.0007).
The failure of surgery alone is attributed to the systemic
nature of the disease at the time of presentation [7,8].
Early and effective systemic chemotherapy and local radi-
otherapy, directed at micro-metastases and added to sur-
gical resection, could lead to increased survival. Many
clinical trials have evaluated the role of adjuvant therapy,BMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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both preoperatively and postoperatively, with conflicting
results. Patients with cervical esophageal cancer are gener-
ally treated with chemoradiation, either preoperatively or
postoperatively, in an attempt to avoid a laryn-
goesophagectomy and preserve the larynx. Although the
majority of studies have been performed in squamous cell
carcinomas, adenocarcinomas were included in some
studies, but a distinction between the two histological
subtypes was not made in this guideline report because
previous studies have not consistently found that they
respond differently to chemotherapy or radiation [9-17].
The large and growing number of patients affected, the
high mortality rates, the geographic variation in practice,
and the large body of good quality research evidence war-
rants a systematic review with meta-analysis.
Methods
This systematic review was developed by the Practice
Guidelines Initiative (PGI) of Cancer Care Ontario's Pro-
gram in Evidence-based Care (PEBC). Evidence was
selected and reviewed by two members of the PGI's Gas-
trointestinal Cancer Disease Site Group (DSG) and two
methodologists. Members of the Gastrointestinal Cancer
DSG disclosed potential conflict of interest information.
This systematic review is a convenient and up-to-date
source of the best available evidence on neoadjuvant or
adjuvant therapy for resectable esophageal cancer. The
body of evidence in this systematic review is primarily
comprised of mature randomized controlled trial data; it
forms the basis of a clinical practice guideline developed
by the Gastrointestinal Cancer DSG published elsewhere
(18). This systematic review and companion practice
guideline are intended to promote evidence-based prac-
tice in Ontario, Canada. The PGI is editorially independ-
ent of Cancer Care Ontario and the Ontario Ministry of
Health and Long-Term Care.
Literature search strategy
The MEDLINE (1966 through October (week 2) 2003),
CANCERLIT (1983 to October 2001), Cochrane Library
(2003, Issue 3), and EMBASE (to week 40, 2003) data-
bases were searched with no language restrictions.
"Esophageal neoplasms" (Medical subject heading
(MeSH)) was combined with "chemotherapy, adjuvant"
(MeSH), "radiotherapy, adjuvant" (MeSH), "immuno-
therapy, adjuvant" (MeSH), and each of the following
phrases used as text words: "preoperative", "neoadju-
vant", "chemotherapy", "radiotherapy", "radiation ther-
apy", "irradiation", "immunotherapy",
"chemoradiotherapy", "chemoradiation", and "hyper-
thermia". These terms were then combined with the
search terms for the following study designs or publica-
tion types: practice guidelines, meta-analyses, and rand-
omized controlled trials. Additionally, the conference
proceedings of the 1997 to 2003 annual meetings of the
American Society of Clinical Oncology (ASCO) and the
1999 to 2002 annual meetings of the American Society for
Therapeutic Radiology and Oncology (ASTRO) were
searched for reports of new or ongoing trials. Relevant
articles and abstracts were reviewed, and the reference lists
from these sources were searched for additional trials.
This formal search was supplemented with published
abstracts from thoracic surgery and oncology conferences,
conversations with colleagues and experts in the field, and
a review of textbooks related to esophageal oncology.
Study selection criteria
Articles were included in this systematic review if they
were fully published reports, abstracts, or meta-analyses
of randomized controlled trials (RCT) of neoadjuvant or
adjuvant treatments compared with surgery alone or sur-
gery plus another treatment in patients with resectable
and operable thoracic esophageal cancer. Data on survival
had to be reported. Other outcomes of interest were
adverse effects and quality of life. Reports of carcinomas
located in the cervical esophagus were excluded.
Synthesizing the evidence
Because diverse treatment strategies were evaluated, the
eligible studies were grouped into 13 basic treatment
approaches (Table 1), and each group was examined sep-
arately. Pooling was conducted using one-year mortality
data for all meta-analyses except for the comparison of
post-operative chemotherapy versus surgery alone, which
was pooled at three years. Any time point selected for
meta-analyses must be clinically credible and relevant but
not so far along the survival curve that wide confidence
intervals result from fewer patients contributing to the
estimate. Since time points prior to the median will gen-
erally ensure that there are sufficient data to be credible,
median survival times, weighted by the size of the treat-
ment arms, were calculated to determine the time point
for each meta-analysis as recommended in the literature
[19]. Studies that did not provide values for survival at the
time of pooling were not included in each meta-analysis,
although they were included in calculating the weighted
median survival time, if values for median survival were
provided. All pooling was performed with Review Man-
ager 4.2.1, available through the Cochrane Collaboration
[Review Manager (RevMan) [Computer program]. Ver-
sion 4.2 for Windows. Oxford, England: The Cochrane
Collaboration, 2003]. Pooled results were expressed as
mortality RR with 95% CI using the random effects
model. An RR less than 1.0 favours neoadjuvant or adju-
vant treatment, and an RR greater than 1.0 favours surgery
alone. All analyses were made based on the intent-to-treat
principle, except where only evaluable patient data were
available.BMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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Potential sources of heterogeneity and sensitivity analysis
Heterogeneity of study results was assessed using a visual
plot of the outcomes and by calculating the X2 (Chi-
square) statistic using a planned cut-off for significance of
p < 0.05. Potential sources of heterogeneity were postu-
lated a priori and included study quality assessed with the
Jadad scale [20] (>2 versus ≤2), full article publication ver-
sus abstract publication, squamous cell versus adenocarci-
noma, type of chemotherapy (cisplatin-containing versus
others), type of surgery (transthoracic versus transhiatal),
and radiotherapy dose (BED>48 versus BED<48). To facil-
itate comparison across trials, radiotherapy dose was con-
verted to biological equivalent dose (same as biological
effective dose) using the equation BED = nd (1+d/α/β),
where n = number of fractions, d = dose per fraction, and
it is assumed that α/β = 10 for tumour effect. Due to lim-
itations inherent with this model, no allowances can be
made for any time gaps in split-course treatments. These
factors were used to explore any significant heterogeneity
of results across the trials. The robustness of our conclu-
sions was examined through subsequent sensitivity analy-
ses using these factors. The sensitivity analysis results are
not detailed, as they would not change the conclusions.
Results
Literature search results
Thirty-four randomized controlled trials were obtained.
Of these, 30 were fully published reports [5,21-25,27-
34,36,37,39,40,42-48,52,56-60], and four were available
in abstract form only [35,41,51,53]. The four-arm trials by
Fok et al [5] and Nygaard et al [24] contributed to multi-
ple comparisons. Additionally, six meta-analyses were
obtained, five fully published [26,38,49,50,55] and one
abstract [54]. Literature search results appear in Table 1.
Outcomes
Preoperative radiotherapy and surgery versus surgery 
alone
Six randomized trials of preoperative radiotherapy and
surgery versus surgery alone are presented in Table 2[5,21-
25]. The radiotherapy regimens varied, using low to mod-
erate doses ranging from 20 Gy in 10 fractions to 53 Gy in
20 fractions. Treatment was delivered between one to four
weeks prior to surgery. Quality-of-life assessments were
not conducted in any of the six trials. The Gastrointestinal
Cancer DSG pooled the five trials that reported one-year
mortality data [5,21,22,24,25] (Figure 1). No statistically
significant difference in the risk of mortality with preoper-
ative radiotherapy at one year compared with surgery
alone was detected (RR, 1.01; 95% CI, 0.88 to 1.16; p =
0.87). No statistical heterogeneity was detected (X2 = 3.61,
p = 0.46).
A published meta-analysis [26] using updated individual
patient data on 1147 patients from five trials [21-25]
detected a hazard ratio for death of 0.89 (95% CI, 0.78 to
1.01; p = 0.062) for preoperative radiotherapy compared
with surgery alone. This meta-analysis included addi-
Table 1: Studies included in this systematic review.
Treatment Approach Number of Trials Reference Numbers Summary of Results
Randomized Controlled Trials
Preoperative RT v. Surgery Alone 6 5*,21–25† Table 2
Postoperative RT v. Surgery Alone 4 5*,27–29,47 Table 3
Preoperative RT v. Postoperative RT 1 5* -
Preoperative RT + Postoperative RT v. Postoperative RT 1 30 -
Preoperative CT v. Surgery Alone 6 24†,32–35‡,37,48 Table 4
Preoperative + Postoperative CT v. Surgery Alone 2 31,36 Table 5
Postoperative CT v. Surgery Alone 3 39–41‡ Table 6
Preoperative CRT v. Surgery Alone 6 24†,42–46,51–53‡ Table 7
Postoperative CT v. Postoperative RT 1 56 -
Preoperative CT v. Preoperative RT 2 24†,57 -
Preoperative CRT v. Preoperative RT 1 58 -
Postoperative Immunotherapy with RT or CRT v. RT or CRT 1 59 -
Preoperative Hyperthermia with CRT v. preoperative CRT 1 60 -
Meta-analyses
Preoperative RT v. Surgery Alone 1 26 -
Preoperative CT v. Surgery Alone 2 38,49,50 -
Preoperative CRT v. Surgery Alone 2 54‡,55 -
Note: CT indicates chemotherapy; CRT, chemoradiation; RT, radiotherapy; v., versus.
* The four-arm trial by Fok et al [5] contributed to three comparisons.
† The four-arm trial by Nygaard et al [24] contributed to four comparisons.
‡ Reports published in abstract form only [35,41,51,53,54].BMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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tional patients from the study by Wang et al. [23] with no
description of why these patients were excluded from the
published report of the trial (a total of 418 patients from
this study were included in the meta-analysis versus 206
included in the trial report). The trial by Fok et al. [5] was
not included in the published meta-analysis.
Postoperative radiotherapy and surgery versus surgery 
alone
Five randomized trials of surgery and postoperative radio-
therapy compared with surgery alone are presented in
Table 3[5,27-29,47]. Although all studies specified the
absence of distant metastases as an inclusion criterion,
Zieren et al. [29] and Teniere et al. [28] included patients
with celiac node involvement (M1 disease). Fok et al. [27]
Table 2: Randomized trials of preoperative radiotherapy (RT) and surgery versus surgery alone.
Study, year 
[Reference]
Participants Number of 
patients
Interventions Median 
Survival 
(Months)
Survival Rate (%) Adverse 
Effects 
(Number of 
Patients)
1 yr 2 yr 3 yr 4 yr 5 yr
Launois et al. 
1981 [21]
124 patients March 1973-
June 1976 France, single 
centre, squamous cell
67 64 – 90 Gy preop 
RT + 
esophagectomy
4 . 5 4 62 01 51 41 0p e r i o p e r a t i v e  
mortality was 
23% in both 
groups.
versus versus versus versus
57 esophagectomy 
(left thoracotomy)
8.2 (mean) 50 35 25 20 12
p = NS, but NR
Gignoux et al. 
1987 [22]
229 patients [dates not 
reported] EORTC, 8 
centres, squamous cell, no 
cervical lesions, no 
previous cancer, no 
previous treatment.
115 33 Gy preop RT + 
esophagectomy
12.3 55 24 20 17 10 tracheosophageal 
fistula, 2; 
bleeding, 1; 
esophagitis, 1; 
respiratory 
deaths, 6
versus versus versus versus versus
114 esophagectomy 12 (mean) 57 30 14 11 9 respiratory 
deaths, 8
No difference in survival (p = 0.94), but RT may delay local recurrence
Wang et al. 
1989 [23]
206 patients June 1977-
May 1985 China, single 
centre histology not 
reported < 65 years age, < 
8 cm length no metastases
104 40 Gy preop RT + 
esophagectomy
NR - - - - 35 leaks, 1; 
perioperative 
deaths, 5
versus versus versus versus versus
102 esophagectomy NR - - - - 30 leaks, 5; 
perioperative 
deaths, 5
No difference in survival (p > 0.05).
Nygaard* 1992 
[24]
108 patients Jan 1983-Jan 
1988 Scandinavia, multi 
centre squamous cell < 75 
years of age, Karnofsky 
score > 50, T1, T2, Nx, M0 
> 21 cm from incisors
58 35 Gy preop RT + 
esophagectomy
10 44 25 21 - - respiratory, 5; 
leaks, 2; 
postoperative 
deaths, 4
versus versus versus versus versus
50 esophagectomy 7 34 13 9 - - respiratory, 5; 
leaks, 2; 
postoperative 
deaths, 5
No difference in survival (p = 0.08).
Arnott 1992 
[25]
176 patients 1979–1983 
Scotland, single centre < 
80 years, squamous cell 
adenocarcinoma, distal 2/3 
esophagus
90 20 Gy preop RT + 
esophagectomy
8 40 22 13 9 9 respiratory, 10; 
postoperative 
deaths, 10
versus versus versus versus versus
86 esophagectomy 
(left 
thoracoabdominal)
8 4 02 82 32 11 7r e s p i r a t o r y ,  5 ;  
postoperative 
deaths, 8; 
surgical, 2
No difference in survival (p = 0.40).
Fok* 1994 [5] 79 patients 1968–1981 
Hong Kong, single centre 
Squamous cell, middle 1/3 
esophagus
40 24–53 Gy preop RT 
+ esophagectomy
11 42 34 24 10 10 respiratory, 20; 
postoperative 
deaths, 12; leaks 
11
versus versus versus versus versus
39 esophagectomy 
(right thoracotomy, 
left neck, and 
abdomen)
22 58 36 24 16 16 respiratory, 15; 
postoperative 
deaths, 3; leaks, 7
No difference in survival.
*Patients randomized to four groups; data shown are for radiotherapy + surgery versus surgery alone.
Note: EORTC, European Organization for Research and Treatment of Cancer.BMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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included patients with positive margins and "a high
chance of residual tumour". In the trials by Fok et al.,
Zieren et al. and Xiao et al., radiotherapy was delivered
within six weeks postoperatively, while the trial by Teniere
et al. specified within three months. The radiotherapy
doses were higher than in the preoperative series. Of note,
Fok et al. employed hypofractionation schedules using
three fractions per week and 3.5 Gy per fraction to total
doses of 49 Gy for patients with negative margins and
52.5 Gy for those with positive margins.
Only Zieren et al. assessed quality of life. The results indi-
cated more rapid recovery of quality of life with surgery
alone compared with postoperative radiotherapy. Three
trials [28,29,47] demonstrated no significant difference in
survival while another [27] found significantly shorter
survival with postoperative radiotherapy and surgery
compared with surgery alone.
The Gastrointestinal Cancer DSG pooled the five trials
that reported one-year mortality data [5,27-29,47] (Figure
2). No significant difference in the risk of mortality with
postoperative radiotherapy and surgery at one year com-
pared with surgery alone was detected (RR, 1.23; 95% CI,
0.95 to 1.59; p = 0.11). No significant statistical heteroge-
neity was detected (X2 = 7.53, p = 0.11). The rate of local
recurrence with radiotherapy was lower in three of the tri-
als [27,28,47], but two trials [27,28] noted this benefit
was achieved at the expense of increased morbidity.
Preoperative radiotherapy versus postoperative 
radiotherapy
One randomized trial evaluated preoperative radiother-
apy versus postoperative radiotherapy with curative
esophagectomy as part of a four-arm study [5]. Patients in
this trial, performed between 1968 and 1981, received
from 24 to 53 Gy preoperatively (n = 40) or 45 to 53 Gy
postoperatively (n = 42). The median survival was 11
months for both groups. No difference in the survival rate
was detected, but there was increased morbidity with pre-
operative radiotherapy. Quality of life was not assessed in
this trial.
Meta-analysis examining preoperative radiotherapy and surgery compared to surgery alone: mortality at one year Figure 1
Meta-analysis examining preoperative radiotherapy and surgery compared to surgery alone: mortality at one 
year. Overall risk ratio = 1.01 (95% CI, 0.88 to 1.16; p = 0.87)
Meta-analysis examining postoperative radiotherapy and surgery compared to surgery alone: mortality at one year Figure 2
Meta-analysis examining postoperative radiotherapy and surgery compared to surgery alone: mortality at one 
year. Overall risk ratio = 1.23 (95% CI, 0.95 to 1.59; p = 0.11)BMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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Preoperative radiotherapy and postoperative 
radiotherapy versus postoperative radiotherapy alone
Iizuka et al. [30] reported a randomized trial of preopera-
tive and postoperative radiotherapy versus postoperative
radiotherapy alone in 364 Japanese patients. In an analy-
sis of 207 eligible patients (157 patients were excluded
because of the extent of disease or operative complica-
tions), preoperative and postoperative radiotherapy was
associated with a significantly higher mortality rate com-
pared with postoperative radiotherapy alone (median sur-
vival was 394 days versus 648 days; p = 0.0069). The
major postoperative complications were pneumonia
(13.5% versus 9.7%) and leakage (11.5% versus 9.7%).
Preoperative chemotherapy and surgery versus surgery 
alone
Seven randomized trials of preoperative chemotherapy
and surgery versus surgery alone are presented in Table
4[24,32-35,37,48]. Of these seven RCTs, six were availa-
ble as fully published reports, and one was available as an
abstract only [35]. Quality of life was not assessed in any
of the trials. Additionally, three meta-analyses were
obtained [38,49,50].
The Gastrointestinal Cancer DSG pooled the available
data on preoperative chemotherapy with surgery versus
surgery alone [24,32-34,37,48] (Figure 3). No significant
Table 3: Randomized trials of surgery and postoperative radiotherapy (RT) versus surgery alone.
Study, year 
[Reference]
Participants Number of 
patients
Interventions Median 
Survival 
(Months)
Survival Rate (%) Adverse Effects 
(Number of 
Patients)
1 yr 2 yr 3 yr 4 yr 5 yr
Fok et al. 1993 
[27]
130 patients July 1986-Dec 1989 
Hong Kong, single centre 
squamous cell adenocarcinoma 
excluded leaks, respiratory 
failure, poor performance, 
metastases
65 esophagectomy + 
49–52.5 Gy postop 
RT
8.7 34 18 16 16 - gastritis, 6; ulcer, 
17; tracheo-
esophageal 
fistulae, 1; 
strictures, 6
versus versus versus versus versus
65 esophagectomy 
(Lewis-Tanner or 
transhiatal or sternal 
split)
15.2 65 25 21 16 - gastritis, 3; ulcer, 
1; tracheo-
esophageal 
fistulae, 0; 
strictures, 6
Shorter survival with RT (p = 0.02). Better local control with RT 
(p = 0.06) but with more complications.
Teniere et al. 
1991 [28]
221 patients Dec 1979-Dec 
1985 France, multi centre 
squamous cell distal 2/3 
esophagus
102 esophagectomy + 
45–55 Gy postop 
RT
18 68 50 27 24 21 minor, 18; major, 
4; death, 1
versus versus versus versus versus
119 esophagectomy 
(transhiatal or right 
thoracotomy with 
stomach or colon 
interposition)
18 73 51 29 22 19 none reported
No difference in survival (p-value not reported). Local or 
regional recurrence was lower with RT (70% versus 85%, p-
value not reported).
Fok* 1994 [5] 79 patients 1968–1981 Hong 
Kong, single centre Squamous 
cell middle 1/3 esophagus
42 esophagectomy (one 
or two stage) + 45–
53 Gy postop RT
11 48 17 17 12 10 respiratory 25; 
postoperative 
deaths 3; leaks 11
versus versus versus versus versus
39 esophagectomy 
(right thoracotomy, 
left neck, and 
abdomen)
22 58 36 24 16 16 respiratory 15; 
postoperative 
deaths 3; leaks 7
No difference in survival.
Zieren et al. 
1995 [29]
68 patients (did not accrue 
entire sample size 68/160) June 
1988-Dec 1991 Germany, single 
centre squamous cell excluded 
cervical location, metastases, 
other cancers, previous 
treatment
33 esophagectomy + 
55.8 Gy postop RT
14 57 29 22 - - tracheo-
esophageal 
fistulae, 1; skin, 
18; strictures, 2
versus versus versus versus versus
35 esophagectomy 
(transhiatal or right 
thoracotomy with 
stomach 
interposition)
13 53 31 20 - - strictures, 1
No difference in survival (p-value not reported).
Xiao et al. 
2003 [47]
495 patients 220 Midplane dose of 
50–60 Gy in 25–30 
fractions over 5–6 
weeks
N R ----4 1 N R
versus versus versus versus
275 Surgery alone NR - - - - 32
p = 0.4474
Note: NR, not reported.
*Patients randomized to four groups; data shown are for surgery + radiotherapy versus surgery alone.BMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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Table 4: Randomized trials of preoperative chemotherapy (CT) and surgery versus surgery alone.
Study, year 
[Reference]
Participants Number 
of patients
Interventions Median 
Survival 
(Months)
Survival Rate (%) Adverse Effects 
(Number of Patients)
1 yr 2 yr 3 yr 4 yr 5 yr
Nygaard* et al. 
1992 [24]
106 patients Jan 1983–Jan 1988 
Scandinavia, multi centre squamous 
cell < 75 years of age Karnofsky 
score > 50 T1, T2, Nx, M0 > 21 cm 
from incisors
56 cisplatin 20 mg/m2 × 5 days 
× 2 cycles bleomycin 10 mg/
m2 × 5 days × 2 cycles + 
esophagectomy
7 31 6 3 - - respiratory, 3; leaks, 3; 
postoperative deaths, 6; 
hematologic, 1; alopecia, 1
versus versus versus versus versus
50 esophagectomy (laparotomy 
and right thoracotomy)
7 34 13 9 - - respiratory, 5; leaks, 2; 
postoperative deaths, 5
No difference in survival (p-value not reported).
Schlag 1992 [32] 46 patients dates not reported 
Germany, single centre squamous 
cell < 68 years of age Karnofsky > 
70 Stage I, II, III
22 cisplatin 20 mg/m2 × 5 days 
× 3 cycles 5-fluorouracil 1 g/
m2 × 5 days × 3 cycles + 
esophagectomy
7.5 20 - - - - vomiting, 11; alopecia, 10; 
fever, 2; bone marrow 
suppression, 5; renal, 2;
versus versus versus versus versus
24 esophagectomy 
(abdominothoracic or 
thoracoabdominocervical 
with gastric or colon 
interposition)
5 3 2 ----n o t  r e p o r t e d
No difference in survival (p = 0.91).
Maipang et al. 
1994 [33]
46 patients Aug 1988–Dec 1990 
Thailand, single centre squamous 
cell < 75 years of age ECOG 1, 2. 
Stage I, II, III distal 2/3 esophagus
24 cisplatin 100 mg/m2 × 1 day 
× 2 cycles vinblastine 3 mg/
m2 × 4 days × 2 cycles 
bleomycin 10 mg/m2 × 5 
days × 2 cycles + 
esophagectomy
17 58 31 31 - - hematologic, 15; vomiting, 
15; alopecia, 14; hepatic, 
3; lung, 1; urologic, 8; 
perioperative deaths, 4
versus versus versus versus versus
22 esophagectomy 
(laparotomy, right 
thoracotomy with gastric or 
colon interposition)
17 85 40 36 - - none reported
p = 0.186 Early survival better in surgery alone 
group.
Law et al. 1997 
[34]
147 patients Dec 1989–Jan 1995 
Hong Kong, single centre squamous 
cell exclude non regional nodes, 
tracheal involvement, metastases
74 cisplatin 100 mg/m2 × 1 day 
× 2 cycles 5-fluorouracil 500 
mg/m2 × 5 days × 2 cycles + 
esophagectomy
16.8 60 44 38 28 28 Anemia, 47; neutropenia, 
43; thrombocytopenia, 12; 
renal, 24; vomiting, 34; 
electrolytes, 21; leaks, 3; 
pulmonary, 10; 
respiratory failure, 14; 
perioperative deaths, 5
versus versus versus versus versus
73 esophagectomy (transhiatal 
or Lewis-Tanner)
13 50 31 14 14 - pulmonary, 11; 
respiratory failure, 22; 
perioperative deaths, 6
p = 0.17 Responders to CT lived longer but non-
responders had lower median survival than 
controls (p = 0.03). Lower local recurrence with 
CT.
Kok et al. 1997 
[35] [abstract]
160 patients 1990–1996 
Netherlands, multi-centered 
Squamous cell
74 cisplatin 80 mg/m2 × 1 day × 
2 cycles, etoposide 100 mg 
IV × 2 days + 200 mg/m2 PO 
× 2 days × 2 cycles + 
esophagectomy Note: CT 
responders received an 
additional 2 cycles of CT 
prior to surgery while non-
responders received only 2 
cycles
18.5 toxic deaths, 1; alopecia, 
67; renal, 10
versus versus versus versus
74 esophagectomy (transhiatal). 11 none reported
Not reported but median survival favoured CT 
(p = 0.002).
MRC OE02 2002 
[37]
802 patients Mar 1992 to June 1998 
United Kingdom, multi-centered 
Resectable esophageal cancer 67% 
adenocarcinoma, 33% squamous or 
undifferentiated.
400 cisplatin 80 mg/m2 × 1 day × 
2 cycles 5-fluorouracil 1 g/
m2 × 4 days × 2 cycles + 
esophagectomy
1 6 . 8 5 94 33 52 82 6p o s t o p e r a t i v e  
complications, 41%; 
postoperative deaths, 10%
versus versus versus versus versus
402 esophagectomy 13.3 54 34 27 20 15 postoperative 
complications, 42%; 
postoperative deaths, 10%
Significant improvement in survival with 
chemotherapy HR = 0.79 (95% CI 0.67 to 0.93; p 
= 0.004)
Ancona et al. 
2001 [48]
94 47 5-FU 1000 mg/m2 CI d1-5 + 
Cisplatin 100 mg/m2 d1
25 75 55 44 42 34 Gr. 3–4 neutropenia; 10 
pts.
versus versus versus versus versus
4 7 S u r g e r y  a l o n e 2 4 7 55 54 13 82 2N R
Note: NR, not reported.
* Patients randomized to four groups; data shown are for chemotherapy + surgery versus surgery alone.BMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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difference in the risk of mortality at one year was detected
(RR, 1.00; 95% CI, 0.83 to 1.19; p = 0.98). No statistical
heterogeneity was detected (X2 = 8.26, p = 0.14).
The first meta-analysis, by Bhansali et al. [38], pooled data
from 12 randomized trials of chemotherapy in a variety of
combinations with radiotherapy with and without sur-
gery, and no benefit for cisplatin-based chemotherapy was
detected (OR, 0.96; 95% CI, 0.75 to 1.22; p > 0.10). This
published meta-analysis included only four of the eight
trials of preoperative chemotherapy versus surgery alone
[24,31-33]. Trials that did not meet the inclusion criteria
for this systematic review, such as trials involving patients
with inoperable esophageal cancer and trials of combined
chemoradiotherapy versus radiotherapy alone in the non-
surgical management of esophageal cancer, were included
in the Bhansali et al. meta-analysis.
The second meta-analysis, by Urschel et al. [49], pooled
data from 11 RCTs (a total of 1,976 patients). These 11
RCTs were graded for quality using the Jadad scale [20].
Pooling detected no statistically significant difference
between combination preoperative chemotherapy with
surgery over surgery alone for survival at either one year
(OR 1.00; 95% CI 0.76–1.30; p = 0.98), two years (OR
0.88; 95% CI 0.62–1.24; p = 0.45), or three years (OR
0.77; 95% CI 0.37–1.59; p = 0.48).
The third meta-analysis [50] was a Cochrane Review
which pooled 11 RCTs (a total of 2,051 patients). Survival
RRs were calculated at one, two, three, four, and five years,
but a statistically significant difference in survival
favouring preoperative chemotherapy was detected only
at five years (RR = 1.44, 95% CI; 1.05–1.97; p = 0.02).
Preoperative and postoperative chemotherapy and 
surgery versus surgery alone
Two randomized trials of preoperative and postoperative
chemotherapy and surgery versus surgery alone [31,36]
(Table 5) were examined. Neither Roth et al. [31] (using a
now out-dated combination of cisplatin, vindesine, and
bleomycin) nor the largest North American trial as
reported by Kelsen et al. [36] (using cisplatin and 5-FU)
detected a statistically significant difference in overall sur-
vival. The Gastrointestinal Cancer DSG pooled these two
trials (Figure 4). No significant difference in the risk of
mortality with preoperative and postoperative chemo-
therapy and surgery compared with surgery alone was
detected (RR, 0.99; 95% CI, 0.81 to 1.21; p = 0.93). No
statistical heterogeneity was detected (X2 = 0.65, p = 0.42).
Postoperative chemotherapy and surgery versus surgery 
alone
Three randomized trials of postoperative chemotherapy
and surgery compared with surgery alone are presented in
Table 6[39-41]. All three trials used cisplatin-based regi-
mens. Pouliquen et al. [39] found no improvement in the
survival rate with postoperative chemotherapy. The
patients were stratified into two groups: complete resec-
tions with or without nodal involvement and, palliative
resections for positive margins or metastatic disease. Only
the completely resected group was included in our analy-
sis. Ando et al. [40] resected early (T1b) carcinomas and
did not find any improvement in survival. In another
study, reported in abstract form, Ando et al. [41] also
found no survival benefit for postoperative chemotherapy
in localized squamous cell carcinoma of the thoracic
esophagus. Pouliquen et al. assessed quality of life and
Meta-analysis examining preoperative chemotherapy and surgery compared to surgery alone: mortality at one year Figure 3
Meta-analysis examining preoperative chemotherapy and surgery compared to surgery alone: mortality at 
one year. Overall risk ratio = 1.00 (95% CI, 0.83 to 1.19; p = 0.98)BMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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found that the duration of improved dysphagia was simi-
lar for both groups.
The Gastrointestinal Cancer DSG pooled the three-year
mortality data for two trials [39,40] (Figure 5). The trial by
Ando et al. [41] could not be included in the pooled anal-
ysis because the abstract did not report three-year survival.
No significant difference in the risk of mortality at three
years for postoperative chemotherapy compared with sur-
gery alone was detected (RR, 0.94; 95% CI, 0.74 to 1.18; p
= 0.59). There was no significant statistical heterogeneity
(X2 = 0.08, p = 0.77).
Preoperative chemotherapy and radiotherapy and surgery 
versus surgery alone
Eight randomized trials of combined modality neoadju-
vant chemotherapy and radiotherapy are presented in
Table 7[24,42-46,51,53]. A ninth trial obtained [52] pro-
vided updated five-year data for another report [44]. None
of the trials reported data on quality of life. In contrast to
the other trials, the study by Walsh et al. [44,52] reported
a significant overall increase in three-year survival with
combined preoperative chemoradiation but was closed
prematurely following an interim analysis. This study was
criticized for the lack of preoperative staging using CT
Table 5: Randomized trials of preoperative chemotherapy (CT) and postoperative chemotherapy (CT) versus surgery alone.
Study, year 
[Reference]
Participants Number 
of 
patients
Interventions Median 
Survival 
(Months)
Survival Rate (%) Adverse Effects (Number 
of Patients)
1 yr 2 yr 3 yr 4 yr 5 yr
Roth et al. 
1988 [31]
39 patients 19 cisplatin 120 mg/m2 × 1 day × 1 cycle 
vindesine 3 mg/m2 × 4 days × 2 cycles 
bleomycin 10 U/m2 × 4 days × 2 cycles 
+ esophagectomy + cisplatin 120 mg/
m2 q 6 wks × 6 months + vindesine 3 
mg/m2 q 12 wks × 6 months
9 50 28 28 - - alopecia, 17; vomiting, 2; 
pneumonia, 1; sepsis, 1; 
neurological, 1; respiratory 
failure, 1; renal, 1; leaks, 1; 
chylothorax, 3; pulmonary 
embolus, 1; wound infection, 1
Nov 1982–May 1986 
NCI, single centre 
squamous cell Stage I, 
II, III
versus versus versus versus versus
20 esophagectomy (transthoracic with 
cervical or thoracic anastomosis)
9 35 15 8 - - leaks, 3; chylothorax, 1; 
pulmonary embolus, 1; 
pneumonia, 1; strictures, 1; 
empyema, 1; subphrenic 
abscess, 1
No difference in survival (p = 0.34). Survival advantage 
in responders and if less than 10% weight loss.
Kelsen et al. 
1998 [36]
467 patients Aug 1990 
to Dec 1995 North 
America, multi-
centered Resectable 
esophageal cancer 55% 
adenocarcinoma 45% 
squamous cell
233 cisplatin 100 mg/m2 × 1 day × 3 cycles 
5-fluorouracil 1 g/m2 × 5 days × 3 
cycles + esophagectomy + cisplatin 75 
mg/m2 × 1 day × 2 cycles if responded
14.9 59 35 23 19 18 minor, 49; major, 53; toxic 
deaths, 9; neutropenia, 68; 
mucositis, 58; postoperative 
deaths, 10
versus versus versus versus versus
234 esophagectomy 16.1 60 37 26 21 20 minor, 67; major, 57; 
postoperative deaths, 13
No survival difference.
Note: NCI, National Cancer Institute
Meta-analysis examining preoperative and postoperative chemotherapy and surgery to surgery alone: mortality at one year Figure 4
Meta-analysis examining preoperative and postoperative chemotherapy and surgery to surgery alone: mortal-
ity at one year. Overall risk ratio = 0.99 (95% CI, 0.81 to 1.21; p = 0.93)BMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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scans, premature closure, and an unusually poor survival
rate in the surgery-alone arm.
The Gastrointestinal Cancer DSG pooled the one-year
mortality data for the six trials with data available at one
year [24,42-46] (Figure 6). No significant difference in the
risk of mortality at one year for preoperative
chemoradiation and surgery compared to surgery alone
was detected (RR, 0.89; 95% CI, 0.76 to 1.03; p = 0.12).
No significant statistical heterogeneity was detected (X2 =
1.67, p = 0.89).
The first meta-analysis, an abstract report by Fiorica et al.
[54], pooled six RCTs comparing preoperative chemoradi-
Table 6: Randomized trials of surgery and postoperative chemotherapy (CT) versus surgery alone.
Study, year 
[Reference]
Participants Number of 
patients
Interventions Median 
Survival 
(Months)
Survival Rate (%) Adverse Effects (Number 
of Patients)
1 yr 2 yr 3 yr 4 yr 5 yr
Pouliquen et al. 
1996 [39]
120 patients total 62 had 
curative resections (no 
residual disease) France, 15 
centres July 1987–Mar 1992 
Excluded tracheal fistula, >30% 
liver metastases, brain 
metastases, node negative 
resections
24 esophagectomy + 
cisplatin 100 mg/m2 × 1 
day × 6–8 cycles 5-
fluorouracil 1000 mg/m2 
× 5 days × 6–8 cycles
20 83 34 32 18 17 For 120 patients: 
tracheoesophageal fistulae, 9; 
sepsis, 5; infections, 11; 
pulmonary, 13; gastrointestinal, 
26; neurologic, 9; neutropenia, 
11; thrombocytopenia, 9; renal, 
15; deaths, 4.
versus versus versus versus versus
38 esophagectomy 20 70 44 32 20 12 tracheoesophageal fistulae, 8; 
sepsis, 4; infections, 9; 
pulmonary, 12; gastrointestinal, 
18; neurologic, 1; neutropenia, 
3; thrombocytopenia, 5; renal, 
1; no deaths.
This analysis based only on complete resections. 
No difference in survival (p-value not reported).
Ando et al. 
1997 [40]
205 patients Japan, multicenter 
Dec 1988–July 1991 
Resectable T1b, < 75 years
105 esophagectomy + 
cisplatin 70 mg/m2 × 1 
day × 2 cycles vindesine 
3 mg/m2 × 2 days × 2 
cycles
57 90 67 58 58 48 anemia, 2; neutropenia, 13; 
vomiting, 13; renal, 8; diarrhea, 
2; infection, 1.
versus versus versus versus versus
100 esophagectomy 
(laparotomy and right 
thoracotomy with 3 
field radical 
lymphadenectomy with 
gastric or colon 
interposition).
47 90 67 54 48 45 none reported
No difference in survival (p = 0.60). Note: 36% unable to complete 
chemotherapy due to 
complications.
Ando et al. 
1999 [41] 
[abstract]
242 patients 120 esophagectomy + 
cisplatin 80 mg/m2 × 2 
cycles 5-fluorouracil 
(800 mg/m2 × 5 days × 2 
cycles
NR - - - - 51 Grade 3 or 4 hematologic or 
non-hematologic toxicities 
were limited in the 
chemotherapy group.
Japan, multicenter Jul 1992–Jan 
1997
versus versus versus versus
122 esophagectomy NR - - - - 61
No difference in survival (p = 0.30)
Meta-analysis examining postoperative chemotherapy and surgery compared to surgery alone: mortality at three years Figure 5
Meta-analysis examining postoperative chemotherapy and surgery compared to surgery alone: mortality at 
three years. Overall risk ratio = 0.94 (95% CI, 0.74 to 1.18; p = 0.59)BMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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Table 7: Randomized trials of preoperative chemoradiation (CRT) and surgery versus surgery alone.
Study, year 
[Reference]
Participants Number 
of 
patients
Interventions Median 
Survival 
(Months)
Survival Rate (%) Adverse Effects (Number of 
Patients)
1 yr 2 yr 3 yr 4 yr 5 yr
Nygaard* et al. 
1992 [24]
103 patients Jan 1983–Jan 1988 Scandinavia, 
multi centre squamous cell, < 75 years of 
age, Karnofsky score > 50, T1, T2, Nx, M0 > 
21 cm from incisors
53 cisplatin 20 mg/m2 × 5 days × 2 
cycles; bleomycin 5 mg/m2 × 5 days × 
2 cycles + 35 Gy sequential 
radiotherapy + esophagectomy
7 39 23 17 - - leaks,2; respiratory, 10
versus versus versus versus versus
50 esophagectomy (laparotomy and 
right thoracotomy)
7 34 13 9 - - respiratory, 5; leaks, 2; 
postoperative deaths, 5.
No difference in survival (p = 0.30).
Le Prise et al. 
1994 [42]
86 patients (stopped early after 104/150 
patients entered) Jan 1988–April 1991 
France, single centre squamous cell, < 70 
years of age, < 15% weight loss excluded 
poor performance, metastases, 
tracheoesophageal fistula
41 cisplatin 100 mg/m2 × 1 day × 2 
cycles 5-fluorouracil 600 mg/m2 × 4 
days × 2 cycles + 20 Gy concurrent 
RT + esophagectomy
11 47 27 19 - - Neurological, 1; hematological, 
7; renal, 2; tracheo-esophageal 
fistulae, 3; infections, 4; effusions, 
2; deaths, 3; pulmonary 
embolism, 1; respiratory failure, 
1.
versus versus versus versus versus
45 esophagectomy 11 47 33 14 - - tracheoesophageal fistulae, 5; 
infections, 7; effusions, 3; deaths, 
3.
No difference in survival (p = 0.56 at 
one year).
Apinop et al. 
1994 [43]
69 patients Thailand, single centre Jan 1986–
Dec 1992 squamous cell carcinoma Mid to 
distal 1/3 esophagus, operable
35 cisplatin 100 mg/m2 × 1 day × 2 
cycles 5-fluorouracil 1000 mg/m2 × 8 
days × 2 cycles + 40 Gy concurrent 
radiotherapy + esophagectomy
9.7 49 30 26 24 24 leaks, 1; toxic deaths, 2; 
respiratory, 2; esophageal 
perforation, 1; cardiovascular, 2; 
electrolytes, 2
versus versus versus versus versus
34 esophagectomy (right thoracotomy) 7.4 392 32 01 91 0l e a k s ,  2 ;  r e s p i r a t o r y ,  2 ;  
cardiovascular, 1
No overall survival difference (p = 0.40 
for median survival). Responders had 
improved survival (p = 0.001).
Walsh et al. 
1996 [44]
113 patients (closed early after 113/190 
patients) May 1990–Sept 1995 Ireland, single 
centre adenocarcinoma < 76 years of age 
excluded poor performance, metastases, 
other cancers, previous chemotherapy or 
radiotherapy
58 cisplatin 75 mg/m2 × 1 day × 2 cycles; 
5-fluorouracil 15 mg/kg × 5 days × 2 
cycles + 40 Gy concurrent RT + 
esophagectomy
16 52 37 32 - - gastrointestinal, 4; hematologic, 
2; cardiac, 15; toxic deaths, 1; 
respiratory, 28; leaks, 2; 
recurrent laryngeal nerve palsy, 
1; chylothorax, 1
versus versus versus versus versus
55 esophagectomy (transhiatal, or 
Lewis-Tanner, or abdominal and left 
thoracotomy)
11 44 26 6 - - leaks, 2; recurrent laryngeal 
nerve palsy, 1; chylothorax, 1; 
respiratory, 32; cardiac, 13
Preoperative chemoradiation + surgery 
prolongs survival compared with 
surgery alone (p = 0.01). Inferior results 
in surgery alone arm.
Bosset et al. 
1994 [45]
282 patients Jan 1989–June 1995 France, 
multi centre squamous cell < 70 years of age 
< 15% weight loss < WHO status 2 
resectable Exclude tracheal fistula, T3N1, 
T4N0, T4N1
143 cisplatin 80 mg/m2 × 3 days × 2 
cycles + 37 Gy concurrent 
radiotherapy + esophagectomy
18.6 69 48 39 35 33 vomiting, 37; neutropenia, 3; 
toxic deaths, 1; postoperative 
deaths, 17; respiratory failure, 6; 
sepsis,7
versus versus versus versus versus
139 esophagectomy (right thoracotomy 
+ cervical anastomosis)
18.6 67 43 37 34 32 sepsis, 2; postoperative deaths, 5 
Note: Trial stopped early 282/
320 due to increased mortality in 
CRT group.
No difference in overall survival (p = 
0.78).
Urba et al. 
2001 [46]
100 patients 1989–1994 Michigan, single 
centre 25% squamous cell 75% 
adenocarcinoma
50 cisplatin 20 mg/m2 × 5 days × 2 
cycles vinblastine 1 mg/m2 × 4 days × 
2 cycles 5-fluorouracil 300 mg/m2 × 
21 days + 45 Gy concurrent 
radiotherapy +esophagectomy
17.6 72 42 30 25 20 grade 3/4 granulocytopenia, 38; 
grade 3/4 thrombocytopenia, 15; 
neutropenic fever, 19; red blood 
cell transfusion, 8; feeding tube, 
31; perioperative deaths, 1
versus versus versus versus versus
50 esophagectomy (transhiatal with 
cervical anastomosis)
16.9 58 38 16 14 10 perioperative deaths, 2; 
anastomotic leaks, 7 versus 5
No difference in overall survival (p = 
0.15).
Burmeister et 
al. 2002 [51]
256 randomized 128† Cisplatin 80 mg/m2 d1 + 5-FU 800 
mg/m2 d2-5 + RT 35 Gy in 15 
fractions
22 NR NR NR NR NR
versus versus versus versus Treatment related mortality 
4.6%
128† Surgery alone 19 NR NR NR NR NR
Lee J-L et al. 
2003 [53] 
[abstract]
102 March 1999 – May 2002 Stage II/III 
resectable esophageal SCC
52 Cisplatin 60 mg/m2 IV d1, 5FU 1,000 
mg/m2 IV d2-5, cisplatin 60 mg/m2 IV 
d22 + RT 45.6 Gy, 1.2 Gy bid d1-28 
+ surgery 3–4 weeks post RT
2 8 . 2 N RN RN RN RN RN R
versus versus versus versus versus
5 0 S u r g e r y  a l o n e 2 7 . 3 N RN RN RN RN RN R
p = 0.67 p = NS
Note: NR, not reported; NS, not significant.
*Patients randomized to four groups; data shown are for chemotherapy + radiotherapy + surgery versus surgery alone.
† number of patients randomized into each treatment arm estimated from total number of patients.BMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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ation and surgery versus surgery alone. A systematic
review, restricted to trials that included only patients with
resectable esophageal carcinoma with no metastatic dis-
ease, obtained six RCTs. A significant difference in three-
year mortality favouring neoadjuvant therapy with sur-
gery versus surgery alone was detected (OR 0.53; 95% CI
0.31–0.92; p = 0.025). A conclusion was made that neo-
adjuvant chemoradiation and surgery significantly
improved three-year survival compared to surgery alone
in patients with resectable esophageal cancer but
acknowledged that the magnitude of the benefit was rela-
tively small. The authors recommend that research to
determine the criteria that would identify patients likely
to benefit from neoadjuvant chemoradiation be
undertaken.
The second meta-analysis, by Urschel et al. [55], pooled
nine RCTs, eight of which were included in this practice
guideline [24,42-46,51,52]. The RCTs were graded for
quality using the Jadad scale. This meta-analysis did not
find a statistically significant difference in mortality at one
year (OR 0.79; 95% CI 0.59–1.06; p = 0.12) or at two
years (OR 0.77; 95% CI 0.59–1.05; p = 0.10). However, as
in the meta-analysis by Fiorica et al. [54], a statistically sig-
nificant difference was found at three years in favour of
preoperative chemoradiation (OR 0.66; 95% CI 0.47–
0.92; p = 0.016). The authors noted that the three-year
survival benefit was most pronounced when chemoradia-
tion was given concurrently (OR 0.45; 95% CI 0.26–0.79;
p = 0.005) as opposed to sequentially (OR 0.82; 95% CI
0.54–1.25; p = 0.36).
To compare the results between the two published meta-
analyses [54,55] with the trials included in this systematic
review, the Gastrointestinal Cancer DSG pooled the data
comparing neoadjuvant chemoradiation with surgery ver-
sus surgery alone at three years and obtained similar
results. A significant difference in the risk of mortality at
three years favouring neoadjuvant chemoradiation with
surgery versus surgery alone was detected (RR = 0.87; 95%
CI 0.80–0.96; p = 0.004). No statistically significant heter-
ogeneity was detected (X2 = 6.59, p = 0.25).
Postoperative chemotherapy and radiotherapy versus 
surgery alone
No randomized trials have evaluated postoperative chem-
otherapy combined with radiation versus surgery alone.
Postoperative chemotherapy versus postoperative 
radiotherapy
One randomized trial evaluated postoperative chemo-
therapy versus postoperative radiotherapy following
curative esophagectomy [56]. Patients in this Japanese
trial received cisplatin and vindesine (n = 126) or radio-
therapy at a dose of 50 Gy (n = 127). The median survival
was 38 months for both groups. No difference in survival
was detected (52% for chemotherapy versus 51% for radi-
otherapy at three years; log-rank p = 0.806). There were
significantly more cases of decreased white blood cell
counts (12 versus 3 for grade 3–4; p = 0.026), elevated
blood urea nitrogen (26 versus 11 for grade 1–2; p =
0.018) and elevated creatinine concentrations (27 versus
9 for grade 1–3; p = 0.006) among patients randomized to
chemotherapy compared with radiotherapy. Quality of
life was not assessed in this trial.
Preoperative chemotherapy versus preoperative 
radiotherapy
Two randomized trials evaluating preoperative chemo-
therapy compared with preoperative radiotherapy were
reviewed [24,57]. Kelsen et al. [57] randomly assigned 96
patients to preoperative radiotherapy or chemotherapy.
Meta-analysis examining preoperative chemoradiation and surgery compared to surgery alone: mortality at one year Figure 6
Meta-analysis examining preoperative chemoradiation and surgery compared to surgery alone: mortality at 
one year. Overall risk ratio = 0.89 (95% CI, 0.76 to 1.03; p = 0.12)BMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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Postoperative crossover therapy (i.e., postoperative radio-
therapy for those who received preoperative
chemotherapy and vice versa) was given to patients who
were found to have unresectable or locally advanced dis-
ease. Only 11 of 48 chemotherapy patients and 9 of 48
radiotherapy patients did not receive additional
postoperative treatment. Overall median survival was
similar in both groups (10.4 months for chemotherapy
versus 12.4 months for radiotherapy; p = 0.61), but the
crossover design precluded proper analysis. In the four-
arm trial by Nygaard et al. [24], preoperative
chemotherapy was compared with preoperative radio-
therapy, and the results demonstrated a significant differ-
ence in survival favouring preoperative radiotherapy
(21% versus 3% at three years; p = 0.01). However, when
compared to surgery alone, there was no benefit to either
preoperative radiation or chemotherapy. Neither trial
report included data on quality of life.
Preoperative chemoradiation versus preoperative 
radiotherapy
One randomized trial evaluated the role of preoperative
bleomycin in addition to radiotherapy [58]. Seventy
patients received preoperative chemoradiation with bleo-
mycin and 63 patients received preoperative radiotherapy
alone. The results demonstrated no significant difference
in survival between the two groups (median survival was
25 weeks versus 26 weeks; survival rate was 25% versus
19% at two years; p = 0.56). There was also no benefit for
bleomycin in the palliation of dysphagia. Quality of life
was not assessed in this trial.
Postoperative immunotherapy in combination with 
radiotherapy or chemoradiation
One Japanese trial evaluated protein-bound polysaccha-
ride (PSK) as an adjunct to postoperative radiotherapy or
chemoradiation in resected esophageal cancer [59]. This
trial involved 174 patients who were randomly assigned
to four treatment groups. The three-year survival rates for
radiotherapy, radiotherapy + PSK, chemoradiotherapy,
and chemoradiotherapy + PSK were 43.3%, 45.5%,
33.5%, and 44.3%, respectively. There was no significant
difference in survival when radiotherapy and radiother-
apy + PSK were compared, or when chemoradiotherapy
and chemoradiotherapy + PSK were compared (log-rank p
= 0.19 for chemoradiotherapy versus chemoradiotherapy
+ PSK). Some patients randomized to PSK experienced
adverse effects, including mild nausea, erythema, liver
dysfunction and leukopenia, but there were no reports of
toxicity that were definitely attributed to PSK. There was
no assessment of quality of life.
Preoperative hyperthermia in combination with 
chemoradiation
One Japanese randomized trial, reported by Kitamura et
al. [60], evaluated preoperative hyperthermia and chemo-
radiotherapy and surgery (n = 32) versus preoperative
chemoradiotherapy and surgery (n = 34). Median survival
was 36 months and 20 months, respectively. The results
showed a significant improvement in the survival rate
(50.4% versus 24.2% at three years; p-value not reported)
and local tumour control with hyperthermia compared
with control. It was reported that both adjuvant treat-
ments were well tolerated and resulted in no postopera-
tive complications. Quality of life was not assessed.
Adverse effects
Adverse effects were inconsistently reported (Tables
2,3,4,5,6,7). Most patients experienced treatment-related
adverse effects associated with radiotherapy or
chemotherapy.
Discussion
Most trials excluded patients with cancers located in the
cervical esophagus, and therefore the interpretation of this
review is limited to tumours in the more distal two thirds.
The options for neoadjuvant or adjuvant therapy for
resectable thoracic esophageal cancer are many. On
reviewing the results of randomized trials and meta-anal-
yses, the Gastrointestinal Cancer DSG did not recom-
mend neoadjuvant or adjuvant therapy based on the
following:
Preoperative radiotherapy does not improve survival
compared with surgery alone. Postoperative radiotherapy
may, in fact, be harmful [27].
Preoperative chemoradiation does not appear to improve
survival compared to surgery alone. Although the pooled
analysis shows that all six studies are in the direction
favouring preoperative chemoradiation at one year, the
pooled estimate did not achieve statistical significance.
When examining the individual trial results, only the trial
by Walsh et al. [44] detected a statistically significant sur-
vival benefit, but this trial has been criticized for its
methodology. The most recent trials, conducted by Bosset
et al. [45] and Urba et al. [46], have five-year data availa-
ble, and neither detected a statistically significant differ-
ence in survival between preoperative chemoradiation
and surgery alone.
Preoperative cisplatin-based chemotherapy does not
appear to improve survival. Four of the seven trials [24,32-
34] detected a significant survival advantage favouring
preoperative cisplatin-based chemotherapy. Kok et al.
[35] reported a survival advantage for chemotherapy butBMC Medicine 2004, 2:35 http://www.biomedcentral.com/1741-7015/2/35
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only reported median survival results in abstract form.
The two largest trials produced conflicting results [36,37].
Kelsen et al. [36] detected no survival advantage, while the
MRC OE02 trial [37] detected a significant survival
advantage for preoperative chemotherapy at two years.
Although all chemotherapy protocols were cisplatin-
based, the varying dosages, the number of cycles com-
pleted, and the other agents used contributed to clinical
heterogeneity.
The available evidence from three randomized trials does
not support the use of postoperative chemotherapy over
surgery alone [39-41].
Two novel approaches, immunotherapy and hyperther-
mia, were studied by two groups in Japan [59,60]. Ogoshi
et al. [59] detected no significant survival benefit for
patients treated with PSK versus without PSK. Although
Kitamura et al. [60] found a significant improvement in
survival and local control favouring preoperative chemo-
radiotherapy with hyperthermia versus without hyper-
thermia, the Gastrointestinal Cancer DSG felt the results
should be interpreted with caution until further confirm-
atory trials are conducted.
Examination of the results of randomized trials, including
the pooled analyses, fails to support the use of preopera-
tive or postoperative adjuvant treatment of any type at this
time for patients with resectable carcinoma of the thoracic
esophagus. Overall, the evidence does not support the use
of neoadjuvant or adjuvant therapy for patients with
resectable cancer of the lower two-thirds of the esophagus.
Surgical resection alone should remain the standard for
localized thoracic esophageal cancer. Patient staging
information can be found in Appendix 1 (Additional file
1).
Future trials should continue to assess multi-modality
treatments for this patient population. For clinicians seek-
ing guidance on treatments for patients with non-resecta-
ble esophageal cancer, the role of radiotherapy alone and
chemoradiation alone without surgery is addressed in
another clinical practice guideline by the Gastrointestinal
Cancer DSG, Combined modality radiotherapy and
chemotherapy in the non-surgical management of localized car-
cinoma of the esophagus [61].
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